Compare ARK Space & Defense Innovation ETF (ARKX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Illumina, Inc. — how do they compare? ARK Space & Defense Innovation ETF trades at $34.43, while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | ILMN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $205.10 |
52-Week Low | $25.46 | $91.00 |
Market Cap | — | $28.96B |
Enterprise Value | — | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKX trades at $34.27, up 3.82% today, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 suggests overbought conditions. The ETF focuses on space exploration and innovation, holding positions in companies like SpaceX and Rocket Lab, benefiting from strong sector tailwinds and recent SpaceX IPO momentum.
Outlook is positive due to growth in the space economy, but risks include high volatility and stretched valuations in key holdings. Investors should weigh exposure to speculative tech against potential regulatory and competitive pressures in the evolving market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
